Cargando…

Surrogate endpoints in early prostate cancer research

Clinical research into clinically-localized prostate cancer (PC) is a highly challenging environment. The protracted durations and large numbers required to achieve survival endpoints have placed much pressure on validating early surrogate endpoints. Further confounding is the predominance of deaths...

Descripción completa

Detalles Bibliográficos
Autor principal:	Williams, Scott
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2018
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6043744/ https://www.ncbi.nlm.nih.gov/pubmed/30050805 http://dx.doi.org/10.21037/tau.2018.05.10

Ejemplares similares

Surrogate endpoints.
por: Ellenberg, S. S.
Publicado: (1993)

Surrogate Endpoints in Medicine
por: Srivastava, Sudhir, et al.
Publicado: (2002)

The evaluation of surrogate endpoints
por: Burzykowski, Tomasz, et al.
Publicado: (2005)

Searching for potential surrogate endpoints of overall survival in clinical trials for patients with prostate cancer
por: Maeda, Hideki, et al.
Publicado: (2021)

Surrogate endpoints and competing risk of death in cardiac arrest research
por: McCredie, Victoria A., et al.
Publicado: (2016)

Surrogate endpoints for early-stage breast cancer: a review of the state of the art, controversies, and future prospects
por: Gion, María, et al.
Publicado: (2021)

The Search for Surrogate Endpoints in Trials in Diffuse Large B‐Cell Lymphoma: The Surrogate Endpoints for Aggressive Lymphoma Project
por: Sargent, Daniel J., et al.
Publicado: (2017)

Overview of Biomarkers and Surrogate Endpoints in Drug Development
por: Wagner, John A.
Publicado: (2002)

Is critical care ready for an economic surrogate endpoint?
por: Wilcox, M Elizabeth, et al.
Publicado: (2015)

Surrogate endpoints… Uncommon for a common man!
por: Kumar, Ashish
Publicado: (2019)

Surrogate Endpoints for Late Kidney Transplantation Failure
por: Naesens, Maarten, et al.
Publicado: (2022)

Review of meta-analyses evaluating surrogate endpoints for overall survival in oncology
por: Sherrill, Beth, et al.
Publicado: (2012)

Need for better reporting of trials with surrogate endpoints: SPIRIT|CONSORT-SURROGATE extensions
por: Ciani, Oriana, et al.
Publicado: (2022)

Early analysis of surrogate endpoints for metastatic melanoma in immune checkpoint inhibitor trials
por: Petrelli, Fausto, et al.
Publicado: (2016)

Bivariate network meta‐analysis for surrogate endpoint evaluation
por: Bujkiewicz, Sylwia, et al.
Publicado: (2019)

Simple Methods for Evaluating 4 Types of Biomarkers: Surrogate Endpoint, Prognostic, Predictive, and Cancer Screening
por: Baker, Stuart G, et al.
Publicado: (2020)

Cardiovascular MRI in clinical trials: expanded applications through novel surrogate endpoints
por: Pitcher, Alex, et al.
Publicado: (2011)

Microdystrophin Expression as a Surrogate Endpoint for Duchenne Muscular Dystrophy Clinical Trials
por: Chamberlain, Jeffrey S., et al.
Publicado: (2023)

Statistical evaluation of surrogate endpoints: a systematic review
por: Ensor, Hannah, et al.
Publicado: (2013)

Biomarkers and Surrogate Endpoints: Lessons Learned From Glaucoma
por: Medeiros, Felipe A.
Publicado: (2017)

Surrogate endpoints in trials: a call for better reporting
por: Ciani, Oriana, et al.
Publicado: (2022)

Surrogate endpoints in global health research: still searching for killer apps and silver bullets?
por: Pai, Madhukar, et al.
Publicado: (2018)

Abstracts of the NIH-FDA Conference “Biomarkers and Surrogate Endpoints: Advancing Clinical Research and Applications”
Publicado: (1998)

Evaluating the evidence behind the surrogate measures included in the FDA's table of surrogate endpoints as supporting approval of cancer drugs
por: Gyawali, Bishal, et al.
Publicado: (2020)

Protocol for the development of SPIRIT and CONSORT extensions for randomised controlled trials with surrogate primary endpoints: SPIRIT-SURROGATE and CONSORT-SURROGATE
por: Manyara, Anthony Muchai, et al.
Publicado: (2022)

Defining Surrogate Endpoints for Clinical Trials in Severe Falciparum Malaria
por: Jeeyapant, Atthanee, et al.
Publicado: (2017)

Uncertainty in the Bayesian meta-analysis of normally distributed surrogate endpoints
por: Bujkiewicz, Sylwia, et al.
Publicado: (2015)

A Systematic Review and Recommendation for Reporting of Surrogate Endpoint Evaluation Using Meta-analyses
por: Xie, Wanling, et al.
Publicado: (2019)

Biomarker changes as surrogate endpoints in early‐phase trials in heart failure with reduced ejection fraction
por: Savarese, Gianluigi, et al.
Publicado: (2022)

Surrogate endpoints in advanced sarcoma trials: a meta-analysis
por: Savina, Marion, et al.
Publicado: (2018)

Value of Adaptive Trials and Surrogate Endpoints for Clinical Decision-Making in Rare Cancers
por: Krendyukov, Andriy, et al.
Publicado: (2021)

Cardiac magnetic resonance imaging parameters as surrogate endpoints in clinical trials of acute myocardial infarction
por: Desch, Steffen, et al.
Publicado: (2011)

Aortic Stiffness as a Surrogate Endpoint to Micro- and Macrovascular Complications in Patients with Type 2 Diabetes
por: Cardoso, Claudia R. L., et al.
Publicado: (2016)

A framework for the definition and interpretation of the use of surrogate endpoints in interventional trials
por: Ciani, Oriana, et al.
Publicado: (2023)

Biomarkers and Surrogate Endpoints: How and When might They Impact Drug Development?
por: Lathia, Chetan D.
Publicado: (2002)

Two Decades of Cardiovascular Trials With Primary Surrogate Endpoints: 1990–2011
por: Bikdeli, Behnood, et al.
Publicado: (2017)

Binary surrogate endpoints in clinical trials from the perspective of case definitions
por: HAHN, ANDREAS, et al.
Publicado: (2021)

A call for better reporting of trials using surrogate primary endpoints
por: Manyara, Anthony Muchai, et al.
Publicado: (2022)

Reply to Commentary by Cummings (2022): Surrogate endpoints extend beyond biomarkers
por: Manyara, Anthony Muchai, et al.
Publicado: (2022)

The Evolving Scenario in the Assessment of Radiological Response for Hepatocellular Carcinoma in the Era of Immunotherapy: Strengths and Weaknesses of Surrogate Endpoints
por: Giuffrida, Paolo, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_t0jhevj2m2m656nkhjm44u1hun